What are Symposia sessions?
Symposia are sessions that focus on a subject, question or issue with a collection of insights from different contributors. These sessions are open to all Annual Meeting delegates and provide the opportunity for our Industry partners to show thought leadership and engage with Annual Meeting delegates through discussions and questions.
Symposia sessions are presented in a variety of formats. In the traditional format, each contributor gets the opportunity to present their perspective and findings on the overall subject, will engage in discussions and is available for questions from the audience. This format allows for several perspectives on one specific topic in only one session. In the debate format, presentations on an argumentative or controversial subject allows contributors to introduce and argue their perspectives, points, and counterpoints. Debates are led by a chair or moderator. In the case study format, the actual case, its circumstances and conditions, its challenges and success factors, along with views of all involved stakeholders is presented inclusively.
How are Symposia sessions evaluated?
Symposia sessions are evaluated according to the HTAi 2019 Annual Meeting Symposia Guidelines, found here.
The objective of the Symposium is to open a multi-stakeholder reflection and explore new approaches to adaptive pathways for evidence generation of life-saving implantable technologies that evolve within their own life cycle. The aim is to discuss with access authorities and payers how HTA in this context “adaptive HTA” could play a progressive, enabling role in the appropriate funding.
Innovative cancer treatment in early settings holds tremendous promise, but appropriate valuation requires consideration of early endpoints and quality of life benefits. What value do we place in sparing patients the experience of living through metastatic disease? The Ideas Factory brings together diverse stakeholders to discuss evidentiary requirements, valuation challenges and solutions to improve patient access to these new innovations.
This symposium focuses on advances in Alzheimer’s disease cost effectiveness modelling and what stakeholders can do to prepare for health technology assessment (HTA) of potential future medicines.
Personalised Health Care (PHC) has the potential to enable better delivery of care, better patient outcomes and more effective research and development of targeted treatment approaches. To ensure that these innovations can gain funding in local health systems, approaches to health economic evaluations and reimbursement and payment mechanisms will all need to evolve and adapt.
The relatively asymptomatic state of nmCRPC patients shapes their priorities and standards for treatment decision-making. Within this population, quality of survival is of such importance that patients may prefer to forego treatment and incremental survival in order to minimize/avoid risk of certain adverse events. Stakeholder perspectives, methodological considerations of holistic risk-benefit assessment, and avenues for HTA incorporation will be discussed.
Assessing the value of new therapies can be challenging when there are diverse perspectives about the relative importance of different types of outcome. Using migraine as an example of diseases that impact the ability to participate in daily activities, we explore patient, HTA and occupational health viewpoints and discuss how a better integration of perspectives can be achieved.
Given the limited resources available for funding healthcare services and interventions, policy and decision-makers are turning to Health Technology Assessment (HTA) in order to ensure their most efficient use. Therefore, we aim to identify the role(s) of Health Technology Assessments (HTAs) and other tools/instruments in assessing the value of medical technologies throughout their lifecycles.
The tremendous growth in healthcare data has the potential to transform health systems and empower patients. Yet to reach that future, institutions, researchers and patients will require access to the growing data sources, as well as the capabilities and intra-institutional networks in place to utilize that data. What are the opportunities and challenges we face before reaching that future?
Schizophrenia is a complex behavioral and cognitive syndrome and among affected patients, since the introduction of second-generation antipsychotics, there has been a rise of interest into the occurrence of metabolic deviations and increased incidence of cardio-vascular events. The proposed Symposium is meant to discuss the societal issues related to schizophrenia and its comorbidities to best support Payers and Policy Makers.
Precision oncology could enable a paradigm shift from organ-based to tumor-agnostic identification of the unique drivers to determine cancer treatment in individual patients. However, these treatments already face challenges in market access under conventional approaches to HTA and demonstration of comparative value. The symposia will illustrate potential disconnects between precision oncology innovation and conventional approaches value assessment in oncology.